natgillin/translations-raw huggingface dataset:
A polypeptide signal sequence, comprising a modified fragment of human immunoglobulin heavy chain binding protein (Bip), wherein the modified fragment of human immunoglobulin heavy chain binding protein (Bip) consists of the amino acid sequence of SEQ ID NO: 20; the amino acid sequence of SEQ ID NO: 21; the amino acid sequence of SEQ ID NO: 22; or the amino acid sequence of SEQ ID NO: 23. 
HR P20181315 T1 PATENTNI ZAHTJEVI Polipeptidna signalna sekvenca, koja sadrži modificirani fragment ljudskog imunoglobulinskog teškog lanca vezujućeg proteina (Bip), naznačena time da modificirani fragment ljudskog imunoglobulinskog teškog lanca vezujućeg proteina (Bip) obuhvaća aminokiselinsku sekvencu SEQ ID NO: 20; aminokiselinsku sekvencu SEQ ID NO: 21; aminokiselinsku sekvencu SEQ ID NO: 22; ili aminokiselinsku sekvencu SEQ ID NO: 23.
Preferably, the second body may have the form of a plate with substantially uniform thickness. 
- < prvu ploču (7) u osnovi ujednačene debljine, i naznačenu time što drugo tijelo također obuhvaća
an external envelope; and at least one profile structure surrounded by the external envelope, the profile structure comprising: 
najmanje jednu strukturu profila (10) okruženu navedenim vanjskim omotačem (11), pri čemu navedena struktura profila (10) sadrži
DETAILED DESCRIPTION OF THE INVENTION The embodiment of the invention illustrated in Figure 1, which preferably has the diameter of a conventional cigarette, includes a short, combustible carbonaceous fuel element 10, an abutting aerosol generating means 12, and a foil lined paper tube 14, which forms the mouthend piece 15 of the article. 
Realizacija izuma ilustrirana na Sl. 1, koja poželjno ima promjer konvencionalne cigarete, uključuje kratak, izgorivi ugljični gorivi element 10, dodirno sredstvo 12 za generiranje aerosola, i papirnu cjev 14 obloženu folijom, koja formira dio 15 usnog kraja proizvoda.
The method of claim 1, wherein the central nervous system disorder is a cognitive disorder selected from the group consisting of delirium, substance induced persisting delirium, dementia, dementia due to HIV disease, dementia due to Huntington's disease, dementia due to Parkinson's disease, behavioral and psychological symptoms of dementia, substance induced persisting dementia, and mild cognitive impairment. 
Spoj prema zahtjevu 11, za uporabu u liječenju ili prevenciji poremećaja središnjeg živčanog sustava izabranih iz grupe koja obuhvaća anksioznost, shizofreniju, migrenu, depresiju, epilepsiju, simptome demencije u ponašanju i psihološke simptome, veliku depresivnu epizodu, depresiju otpornu na liječenje, bipolarnu depresiju, opći anksiozni poremećaj, post-traumatski stresni poremećaj, bipolarnu maniju, ovisnost i miješanu anksioznost i depresiju.
applying the allele frequencies to a mixture model to obtain an estimate of the fraction of fetal DNA in the DNA obtained from the blood of the individual carrying the fetus, 
pri čemu mapiranje DNK segmenata, dobivenih iz krvi osobe koja nosi fetus, obuhvaća računalno mapiranje navedenih segmenata u okviru baze podataka polimorfizama;
A topical formulation for use according to claims 1-4 for administering in conjunction with one or more additional therapeutic agents for the treatment of neovascular disorders. A topical formulation for use according to claim 5 wherein the one or more additional therapeutic agent is pegaptanib and/or ranibizumab. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 1-4, naznačena time što je namijenjena za primjenu uz jedno ili više dodatnih terapijskih sredstava za liječenje neovaskularnih poremećaja, Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevom 5, naznačena time što jedno ili više dodatnih terapijskih sredstava je pegaptanib i/ili ranibizumab,
A nucleic acid molecule encoding a polypeptide chain according to claim 11 or 12. 
Molekula nukleinske kiseline koja kodira polipeptidni lanac dimerne antigen-vezujuće molekule prema bilo kojem od patentnih zahtjeva 1 do 6.
an epitope comprising a peptide fragment of proteolipid protein (PLP); each peptide fragment being in linear or cyclic form; 
epitop koji sadrži peptidni fragment proteolipidnog proteina (PLP) u linearnom ili cikličkom obliku;
A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća konjugat u skladu s bilo kojim od zahtjeva 1 do 7,i farmaceutski prikladan razrjeđivač, nosač ili pomoćno sredstvo.
and its salts, solvates and solvates of the salts. 
ro H ili jedna od njegovih soli, njegovih solvata 1 solvati njegovih soli.
b is absent or represents C1-C3alkylene, C2-C3alkenylene; or a group selected from -CH2NH-, -CH2O-, and -CH2S-, said group being linked to G via the nitrogen, oxygen or sulfur atom. 
b je odsutan ili predstavlja C1-C3alkilen, C2-C3alkenilen ili skupina koju se bira između -CH2NH-, -CH2O- i -CH2S-, gdje je navedena skupina vezana na G preko atoma dušika, kisika ili sumpora.
In addition to the compounds TPI 287, TPI 285, and TPI 251, various other 9,10-a,a hydroxy taxane derivatives have also exhibited significant inhibition against various cancer cell lines. 
Uz spojeve TPI 287, TPI 2851 TPI 251, razni drugi 9,10-o,a hidroksi derivati taksana su također pokazali značajnu inhibiciju u odnosu na razne stanične linije karcinoma.
A system of claim 5(a) which further comprises a deposition zone in which there are arranged a plurality of deposition devices (465, 466, 467) along the pathway for depositing reagents on the solid phase in spatially addressed manner. 
Sustav sukladno patentnom zahtjevu 5 (a), naznačen time, da još obuhvaća zonu taloženja u kojoj je raspoređeno više uređaja (465, 466, 467) za taloženje duž putanje za odlaganje reagenasa na čvrstoj fazi na način da se štedi prostor.
As at least a part of the packaging is made of a metal material it is essential that the packaging does not shield the magnetic field and/or the electromagnetic signals. 
Kako je barem jedan dio pakiranja načinjen od metalnog materijala, bitno je da pakiranje ne zaklanja magnetsko polje i/ili elektromagnetske signale.
The method of claim 32, wherein the disease is rheumatoid arthritis. 
Spoj za upotrebu prema zahtjevu 18, pri čemu je bolest reumatoidni artritis.
The solid dosage form of claim 11 wherein the polymorphic crystalline form of a compound of Formula I is present from about 75% to about 99.99% of the total weight of tiacumicins. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, naznačen time što je polimorf Formule I prisutan u najmanje 95% od ukupne težine, te gdje je farmaceutski pripravak u čvrstom obliku doziranja.
Parenteral Preparations 
(3) Parenteralni pripravci
The computer system of claim 6, wherein the executing further comprises dynamically determining the boundary, the dynamically determining using a specified type of boundary and one or more characteristics of the processor. The computer program product of claim 1, wherein the boundary is an end boundary of the block of main memory. The computer system of claim 6, wherein the boundary is an end boundary of the block of main memory. 
Računalni sustav u skladu s patentnim zahtjevom 10. ili patentnim zahtjevom 11., naznačen time što se izvršavanje dodatno sastoji od dinamičnog određivanja granica, pri čemu se kod dinamičnog određivanja upotrebljava specificirani tip granice i jedna ili više karakteristika procesora. Računalni sustav u skladu s patentnim zahtjevom 12., naznačen time što se određivanje udaljenosti sastoji od određivanja krajnje adrese kod koje brojenje treba stati.
The method of any one of claims 1 to 10 comprising enriching or isolating a NKX6-1 positive population of cells; wherein the enriching or isolating step comprises contacting the population of cells with an HPx epitope detecting antibody and isolating or partially purifying the HPx1 and/or HPx2 bound subpopulation of cells. 
Postupak sukladno bilo kojem patentnom zahtjevu 1 do 10 obuhvaća obogaćivanje ili izoliranje NKX6-I pozitivne populacije stanica; pri čemu korak obogaćivanja ili izoliranja obuhvaća kontaktiranje populacija stanica s protutijelom za detektiranje HPx epitopa i izoliranje ili djelomično pročišćavanje HPx1 i/ili podpopulacije stanica vezane na HPx2.
the third stream decompressed by the decompressing means is in a gas-liquid mixed state and is supplied to a gas-liquid separator (23). The liquefied gas treatment system according to claim 1, wherein a liquid component separated in the gas-liquid separator (23) returns to the storage tank. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se treću struju, dekomprimiranu u plinsko-tekuće miješano stanje, vraća u spremnik za teret (11).
The system of claim 3 further comprising a controller component configured to simultaneously control the range of current supplied by the first and second stimulation components and establishing the upper limit of current of the first component at not greater than the current at the second stimulation component and dynamically adjusting the upper limit simultaneously with adjustment of the second current. 
Sustav sukladno zahtjevu 1 nadalje obuhvaća kontrolnu komponentu konfiguriranu na način da simultano kontrolira opseg struje koja se pruža pomoću prve i druge stimulacijske komponente i uspostavlja gornju granicu struje prve komponente ne višu od struje na drugoj stimulacijskoj komponenti i dimamički prilagođava gornju granicu simultano s prilagođavanjem druge struje.
For example, suitable bases are alkaline earth metal amides, such as sodium bis(trimethylsilyl)amide. 
Na primjer, prikladne baze su metalni amidi zemno-alkalisjkih metala, poput natrij bis(trimetilsulfil)amida.
A uracil compound of formula (I) or a salt thereof: wherein: 
Spoj uracila predstavljen općom formulom (I) ili njegova sol:
binds to active MIF does not bind to non-active MIF. 
Cc) veže se na aktivni MIF d) ne veže se na neaktivni MIF.
In one embodiment, said calcium-carbonate containing material of step a) is provided in the form of an aqueous suspension. In this embodiment, said suspension has a content of calcium carbonate containing material within the range of 1 wt.-% to 79 wt.-%, more preferably of 3 wt.-% to 78 wt.-%, even more preferably of 55 wt.-% to 75 wt.-%, based on the weight of the suspension. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time da je navedeni materijal koji sadrži kalcijev karbonat iz koraka a) osiguran u obliku vodene suspenzije, te poželjno ima udio materijala koji sadrži kalcijev karbonat u rasponu od 1 tež-% do 79 tež-%, poželjnije 3 tež.% do 78 tež.%, te još poželjnije 55 tež-% do 75 tež-
Cooling system according to Claim 1, wherein comprising at least one cabin (280) in which said liquid supply kit (250), the flow control kit (252) and the control unit (260) are located. 
Rashladni sustav prema patentnom zahtjevu 1, naznačen time da, sadrži najmanje jednu kabinu (280) u kojoj se nalaze spomenuti komplet (250) za dovod tekućine, komplet (252) za reguliranje protoka 1 upravljačka jedinica
As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated”. In one embodiment, the additional agent is selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator other than a compound of the present invention, or a nutritional agent. 
HR P20180300 T1 PATENTNI ZAHTJEVI snom Farmaceutski pripravak koji sadrži spoj N-(5-hidroksi-2,4-diterc-butil-fenil)-4-okso-1H-kinolin-3-karboksamid ili njegovu farmaceutski prihvatljivu sol, pri čemu navedeni pripravak nadalje sadrži: a) farmaceutski prihvatljiv nosač ili adjuvant; i b) dodatno sredstvo odabrano od mukolitičkog sredstva, bronhodilatatora, antibiotika, antiinfektivnog sredstva, protuupalnog sredstva, modulatora cistično fibroznog transmembranskog receptora (CFTR) ili prehrambenog sredstva.
the reductive amination of a compound of the formula (XXXVI): with HNR2R3 in the presence of a reducing agent; and optionally (c) the conversion of one compound of the formula (I) into another compound of the formula (I). 
OR N-N H (XXXVI) HR P20100675 TI s HNRČR* u prisutnosti reducensa; i po izboru (c) pretvorbu jednog spoja formule (I) u drugi spoj formule (I).
Use of a compound according to any one of claims 1 to 32 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response, and all diseases and conditions induced by or associated with an excessive secretion of TNF-a and IL-1. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 32, ili njegove farmaceutski prihvatljive soli ili solvata, u proizvodnji medikamenta za liječenje upalnih bolesti, poremećaja i stanja, naznačena time, ili povezana s neželjenim upalnim imunosnim odgovorom i svim bolestima i stanjima induciran ili povezanim s prekomjernim lučenjem TNF-q i IL-1.
The compounds of the invention as the free base or the salt thereof may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. 
Spojevi izuma kao slobodne baze ili njezine soli mogu se davati sami ili u kombinaciji s farmaceutski prihvatljivim nosačima ili ekscipijentima, bilo u jednokratnoj ili u višestrukim dozama.
— — A method of controlling heartworm disease in a dog, the method comprising administering to said dog an implant comprising ivermectin, wherein said implant maintains a concentration of ivermectin at about 0.10 ng per mL of plasma during a period of 6 months to 12 months after administering the implant, said concentration of ivermectin being effective to control Dirofilaria immitis or Dirofilaria repens infestation. 
Pribor za uporabu u kontroli parazitske zaraze srčanim crvom u psu, koji sadrži implant koji sadrži efektivnu dozu ivermektina za kontroliranje zaraze Dirofilaria immitis-om i/ili Dirofilaria repens-om 1 upute za liječenje 1/li prevenciju u navedenom psu, pri čemu je navedena efektivna doza količina dovoljna da se ivermektin isporučuje pod uvjetima koji omogućuju održavanje koncentracije od 0,1 ng po mL plazme kroz period od barem 6 mjeseci.
The inside front wall also features fixing substance along its edge. 
Unutarnji prednji zid također ima uz svoj rub tvar za fiksiranje.
processing said three-dimensional data to simulate a tooth restoration part having an inner shape determined so as to fit a predetermined remaining part of tooth structure of said tooth after removal of the predetermined part of tooth structure to be removed, and having an outer shape determined so as to fit together with remaining neighbouring teeth; and producing said tooth restoration part in advance. Method according to claim 6, characterized in that said method further comprises: 
obrade navedenih trodimenzijskih podataka kako bi se simuliralo restaurirani dio zuba koji ima određeni unutarnji oblik, kako bi odgovarao zadanom preostalom dijelu zubne strukture navedenog zuba nakon uklanjanja zadanog dijela zubne strukture kojeg treba ukloniti, te koji ima određeni vanjski oblik, kako bi se uklopio među preostale susjedne zube; i proizvodnje restauriranog dijela navedenog zuba unaprijed.
As an alternative, the wall elements can be prefabricated, with all windows, doors, lines and/or other accessories mounted in the production facility. 
Kao alternativa, zidni elementi mogu se unaprijed izraditi, sa svim prozorima, vratima, vodovima i/ili drugom dodatnom opremom ugrađenom u proizvodnom pogonu.
Ammonia was found very effective copper fixative long time ago, but due to its emissions this formulation newer came into extensive commercial use. 
Za amonijak je davno ustanovljeno da je vrlo djelotvoran fiksator bakra, ali zbog njegovog isparavanja ova formulacija nikad nije ušla u široku komercijalnu upotrebu.
The device of claim 6, wherein the at least one seal is a polymer film that is ultrasonically welded to the porous scaffold. 
Uređaj sukladno zahtjevu 6, pri čemu je najmanje jedan zatvarač polimerni film koji je ultrazvučno zavaren za poroznu noseću strukturu.
In a particular embodiment, the buffer of the instant compositions is sodium phosphate (e.g., about 5 mM to about 50 mM sodium phosphate, about 10 mM to about 30 mM sodium phosphate, or about 20 mM sodium phosphate). 
Pripravak za uporabu prema zahtjevu 1, naznačen time što pripravak sadrži natrijev fosfatni pufer, proizvoljno pri čemu pripravak sadrži 5 mM do 50 mM natrijevog fosfata, 10 mM do 30 mM natrijevog fosfata, ili 20 mM natrijevog fosfata.
(c10) an antigen-binding site comprising an L chain CDR1, 2, and 3 amino acid sequences of SEQ ID NOs: 177, 178, and 179 (L chain CDR of L180), respectively; 
(c10) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence L-lanca CDR-područja 1, 213 od SEQ ID NO: 177, 178 odnosno 179 (L-lanac CDR- područja od L180); ili
after the reacting in step a), reacting the compound of Formula IIId with an acid, followed by reacting with pinacol to form the compound of Formula IIIb-1; wherein: 
Illq i b) nakon reakcije u koraku a), reakciju spoja s formulom IIId s kiselinom, nakon čega slijedi reakcija s pinakolom da se dobije spoj s formulom IIIb-1; pri čemu:
For example, the reaction may be carried out using potassium carbonate as a suitable base, N -methylpyrrolidin-2-one as a suitable diluent and at a temperature of about 105°C. 
Na primjer, reakcija se može provesti koristeći kalij-karbonat kao prikladnu bazu, N-metilpirolidin-2-on kao prikladni razrjeđivač pri temperaturi od otprilike 105 *C.
Thus the concentration of the uracil is a surrogate marker for the intensity of the smell. 
Prema tome koncentracija uracila je nadomjesni marker za intenzitet mirisa.
The process according to claim 1, wherein said process also comprises a step e) of stopping the crosslinking, consisting of exposing the crosslinked hydrogel to conditions capable of stopping the crosslinking thereof, wherein the stopping step is carried out before, jointly with or after the recovering step d). 
zaustavljanje umrežavanja izlaganjem umreženog gela uvjetima koji su povoljni za zaustavljanje njegovog umrežavanja, ovaj neobavezni korak e) provodi se prije, zajedno s ili nakon koraka obnavljanja d).
a TCR expression vector which comprises nucleic acid as claimed in claim 13 encoding in a single open reading frame, or two distinct open reading frames, the alpha chain and the beta chain respectively; or 
TCR ekspresijski vektor koji sadrži nukleinsku kiselinu sukladno patentnom zahtjevu 8 koja kodira u jednom otvorenom okviru čitanja, ili dva odvojena otvorena okvira čitanja, alfa lanac i beta lanac redom; ili
Decitabine Thyroid cancer, myelodysplastic syndromes, melanoma or renal cell carcinoma. 
Decitabin Karcinom štitnjače, -mijelodisplastični - sindromi, melanom ili karcinom bubrega
Additional Statements of Invention 
(54) Naziv izuma:
The components (B) are known. 
(B) spoj fluopiram.
In some embodiments, the mixture model accounts for sequencing error. In certain embodiments, the methods additionally include computationally removing allele frequencies for polymorphisms identified has being heterozygous in both the fetus and the pregnant individual. 
Postupak prema patentnom zahtjevu 1, naznačen time što nadalje sadrži, prije postupka (c), računalno uklanjanje učestalosti alela za polimorfizme koji su identificirani kao heterozigotni i kod fetusa i kod trudne osobe.
The dehydration reaction is typically carried out at a temperature lower than room temperature, for example at around 0-5°C. 
Reakcija dehidriranja se obično provodi pri temperaturi nižoj od sobne temperature, na primjer na oko 0-5*C.
The method according to claim 1, wherein the predefined temperature of the disk is the target temperature of the strand-like material. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je zadana temperatura najmanje jednog diska (10) ciljana temperatura predmeta u obliku strune (22).
the transplant is monitored to determine the lowest effective dose of an immunosuppressive drug; 
(ili) transplantat se prati radi utvrđivanja najniže djelotvorne doze imunosupresivnog lijeka;
The power-generating system of claim 12, wherein each of the plurality of airfoil-shaped profiles is made of a material selected from the group consisting of wood, plastic, resins, composites, carbon materials, and formed sheet metal. 
Fleksibilno krilo (20) prema Zahtjevu 12, gdje je svaki od većeg broja aerodinamično oblikovanih profila (30) izrađen od materijala odabranog iz grupe koja sadrži drvo, plastiku, smole, kompozite, ugljične materijale 1 materijale iz formiranih listova.
The immunoconjugate of claims 11, wherein the immunoconjugate is of a structure selected from the group consisting of: and wherein Val is valine and Cit is citrulline. 
Protutijelo anti-CD79b cisteinskog inženjeringa prema zahtjevu 18, naznačeno time, da je skupina lijeka (D) odabrana iz skupine koju čine majtanzinoid i auristatin.
coupling an amino-terminal protected aspartic acid residue having a protected carboxyl side chain to a tryptophan-proline dipeptide through the tryptophan residue of the dipeptide, and removing the amino-terminal protecting group from the aspartic acid residue, thereby forming a protected 4-6 eptifibatide fragment of the formula: 
P,-Har-Gly-OH; kopuliranje amino-terminalno zaštićenog ostatka aspartinske kiseline, koji ima zaštićen karboksilni postrani lanac, na triptofan-prolin dipeptid preko triptofanskog ostatka dipeptida, i uklanjanje amino-terminalne zaštitne skupine iz ostatka aspartinske kiseline, da na taj način nastane zaštićeni fragment 4-6 eptifibatida formule:
The system according to 9, wherein the User Equipment UE (105) receives a status of the handover request from the target cell with the highest weighted average of the RSRP values. 
Sustav u skladu s patentnim zahtjevom 9, naznačen time što Korisnička Oprema UE (105) prima stanje zahtjeva za prelazak 1z ciljane ćelije s najvišim ponderiranim prosjekom RSRP vrijednosti.
Use of Claim 87, wherein the therapeutic agent is capable of alleviating at least one symptom of the AOID and is a steroid, a non-steroidal anti-inflammatory or a TNF inhibitor. 
Uporaba u skladu sa zahtjevom 87, naznačena time, da je terapeutsko sredstvo sposobno ublažiti barem jedan simptom AOID te je steroid, ne-steroidno protu-upalno sredstvo ili TNF inhibitor.
Then, on the basis of the known deformation characteristics of the basic part 2 and the known deformation characteristics of the inserts 3, 4, 5, the material from which the inserts 3, 4, 5 have to be selected can be calculated by a computer model in order to make a mattress 1 for the person, such that when this person is lying sideways on the mattress 1, the degree of compression in the shoulder, waist and hip zones is equal to the target values. 
Metoda prema zahtjevu 4, naznačena time što na temelju poznatih deformacijskih karakteristika osnovnog dijela (2) i poznatih deformacijskih karakteristika umetaka (3,4,5), materijal od kojeg umeci (3,4,5) mogu biti izabrani može se izračunati pomoću računalnog modela kako bi se napravio madrac za osobu, takav da je stupanj kompresije u zonama ramena, struka i kukova jednak ciljnim vrijednostima, kad ta osoba leži bočno na madracu.
A molecule comprising a saccharide of the formula: wherein 
Molekula koja sadrži saharid formule:
In the furanose form, bonds are likely through either of these primary alcohols at the 1 or the 6 position. 
U furanoznom obliku veze su vjerojatne kroz bilo koji od tih primarnih alkohola na položaju 1 ili 6.
The nucleic acid complex according to claim 1, wherein the amount of the highly branched cyclic dextrin is 1 to 4000 parts by weight per part by weight of the nucleic acid. 
Kompleks nukleinske kiseline u skladu sa zahtjevom 1, naznačen time, da količina visoko razgranatog cikličkog dekstrina je 1 do 4000 težinskih dijelova po jednom težinskom dijelu nukleinske kiseline.